Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Contract Services
Return to: PBR Home | Contract Research & Services | Contract Services | News
Search Refinements

Contract Services News

View news from other Pharmaceutical sectors:
1-15 of 2355 results
Debiopharm acquires ImmunoGen’s ADC IMGN529/Debio 1562
Debiopharm International has acquired ImmunoGen's IMGN529/Debio 1562, a clinical-stage anti-CD37 ADC for the treatment of patients with B-cell malignancies, such as non-Hodgkin lymphomas (NHL).
Contract Research & Services > Contract Services > News
INC Research, inVentiv agree to merge in $4.6bn deal
By PBR Staff Writer
INC Research has agreed to acquire US-based contract research organization (CRO) inVentiv Health in all stock deal worth nearly $4.6bn.
Contract Research & Services > Contract Services > News
Novartis licenses CAR-T patents from Celyad
Celyad has granted Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents.
Contract Research & Services > Contract Services > News
Akebia expands anemia drug collaboration with Otsuka
By PBR Staff Writer
US-based Akebia Therapeutics has expanded its collaboration with Japan's Otsuka Pharmaceutical on an anemia treatment.
Contract Research & Services > Contract Services > News
Immune Pharmaceuticals licenses cancer treatment's Latin America rights to Pint
Immune Pharmaceuticals has entered into a letter of intent with Pint Pharma regarding license and commercializion of Ceplene in Latin America.
Contract Research & Services > Contract Services > News
PureTech signs licensing and equity deal with Novartis to advance clinical stage mTORC1 programs
PureTech Health has signed a licensing and equity agreement with Novartis to advance two clinical-stage programs targeting the mechanistic target of rapamycin complex 1 (mTORC1) pathway.
Contract Research & Services > Contract Services > News
PTC Therapeutics agrees to buy Marathon's DMD drug for $140m
PTC Therapeutics has agreed to acquire all rights to Emflaza (deflazacort) from Marathon Pharmaceuticals.
Contract Research & Services > Contract Services > News
Advaxis licenses antigen delivery technology to Sellas for cancer immunotherapy development
Advaxis has licensed its Lm-based antigen delivery technology to Sellas, under a cancer immunotherapy collaboration that could generate up to $358m for Advaxis.
Contract Research & Services > Contract Services > News
Horizon Discovery signs master service deal with top three global pharmaceutical firm
Horizon Discovery Group has signed a Master Services Agreement (MSA) with a top three global pharmaceutical company, extending support for their drug discovery and development efforts to its full suite of services.
Contract Research & Services > Contract Services > News
Neurotrope signs licensing deal for accelerated synthesis of Alzheimer’s drug Bryostatin-1
Neurotrope has signed a licensing agreement with Stanford University for an accelerated synthesis of Alzheimer's drug bryostatin-1.
Contract Research & Services > Contract Services > News
Abzena signs licensing deal for ThioBridge antibody drug conjugate linker technology
Abzena has entered into a licensing agreement with with a San Diego-based biopharmaceutical firm for its novel site-specific ThioBridge antibody drug conjugate (ADC) linker technology.
Contract Research & Services > Contract Services > News
Cumberland Pharmaceuticals, Clinigen sign US commercialization deal for Totect
Cumberland Pharmaceuticals and Clinigen Group have signed an exclusive agreement to commercialize the oncology support drug, Totect (dexrazoxane hydrochloride) in the US.
Contract Research & Services > Contract Services > News
Novartis signs potential $1bn deal with Ionis and Akcea on cardiovascular treatments
By PBR Staff Writer
Novartis has agreed to pay more than $1bn to Ionis Pharmaceuticals and its subsidiary Akcea Therapeutics for the rights to two cardiovascular drugs.
Contract Research & Services > Contract Services > News
Dermavant licenses cerdulatinib from Portola for topical applications
Dermavant Sciences has signed an exclusive worldwide licensing agreement with Portola Pharmaceuticals for the development and commercialization of cerdulatinib in topical applications beyond oncology.
Contract Research & Services > Contract Services > News
Bristol-Myers secures rights to PsiOxus’ armed oncolytic virus
By PBR Staff Writer
Bristol-Myers Squibb has signed an agreement worth up to $936m plus royalties to secure global rights to an armed oncolytic virus being developed by PsiOxus Therapeutics to treat solid tumors.
Contract Research & Services > Contract Services > News
1-15 of 2355 results